Morozoff (TSE:2217) has just posted a soft Q3 2026 print, with revenue of ¥6.1 billion and a basic EPS of -¥23.41 as net income slipped to a loss of ¥473 million. Looking across recent quarters, the company has seen revenue move from ¥5.9 billion in Q3 2025 to ¥9.0 billion in Q1 2026, before easing back to ¥7.2 billion in Q2 and ¥6.1 billion in Q3, while EPS swung from -¥6.88 to ¥52.89, then ¥13.06, ¥0.35 and now back into negative territory. For investors, the latest quarter reads as a step back for profitability, with margins clearly under pressure even as the top line holds in a relatively tight range.
See our full analysis for Morozoff.With the headline numbers on the table, the next step is to see how this latest margin picture lines up with the prevailing narratives around Morozoff, and where the story investors tell themselves might need a rethink.
Curious how numbers become stories that shape markets? Explore Community Narratives
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Morozoff's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
Morozoff’s shrinking margins, volatile quarterly earnings and stretched valuation versus its DCF fair value all suggest investors face meaningful downside risk at today’s price.
If you want better odds on price and fundamentals lining up, use our these 903 undervalued stocks based on cash flows to quickly find candidates where valuation looks far more compelling right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com